Synthesis and Anti-HBV Evaluation of 5-Halogenated 2'-Deoxy-2'-β-fluoro-4'-azido Pyrimidine Nucleosides

  • Guo Meichao ,
  • Kang Jinfeng ,
  • Hou Jiao ,
  • Zhang Qianqian ,
  • Yu Wenquan ,
  • Chang Junbiao
Expand
  • a College of Chemistry, Zhengzhou University, Zhengzhou 450001;
    b Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, He'nan 453007

Received date: 2019-07-30

  Revised date: 2019-09-09

  Online published: 2019-09-18

Supported by

Project supported by the National Natural Science Foundation of China (Nos. 81773570, U1804283) and the Young Backbone Teachers Fund of Zhengzhou University (No. 2017ZDGGJS020).

Abstract

A series of 5-halogenated 2'-deoxy-2'-β-fluoro-4'-azido pyrimidine nucleosides were synthesized from m-chloro-benzoyl protected 2'-deoxy-2'-β-fluoro-4'-azido uridine via ammonium cerium nitrate (CAN)-mediated halogenation, activation by triazole, amination, and deprotection. In vitro biological evaluation demonstrated that 5-chloro (6a) and 5-iodo (6c) nucleoside derivatives possess potent anti-HBV (hepatitis B virus) activity with low cytotoxicity.

Cite this article

Guo Meichao , Kang Jinfeng , Hou Jiao , Zhang Qianqian , Yu Wenquan , Chang Junbiao . Synthesis and Anti-HBV Evaluation of 5-Halogenated 2'-Deoxy-2'-β-fluoro-4'-azido Pyrimidine Nucleosides[J]. Chinese Journal of Organic Chemistry, 2020 , 40(1) : 221 -225 . DOI: 10.6023/cjoc201907054

References

[1] World Health Organization Hepatitis B (18 July 2018). https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b.(accessed on 25 June 2019).
[2] Hoofnagle, J. H.; di Bisceglie, A. M. New Engl. J. Med. 1997, 336, 347.
[3] Mailliard, M. E.; Gollan, J. L. Annu. Rev. Med. 2006, 57, 155.
[4] Liaw, Y. F.; Chu, C. M. Lancet 2009, 373, 582.
[5] Chang, J. EP 2177527, 2013; US 8835615, 2014[Chem. Abstr. 2008, 149, 32518].
[6] Wang, Q.; Hu, W.; Wang, S.; Pan, Z.; Tao, L.; Guo, X.; Qian, K.; Chen, C.-H.; Lee, K.-H.; Chang, J. Eur. J. Med. Chem. 2011, 46, 4178.
[7] Zheng, L.; Wang, Q.; Yang, X.; Guo, X.; Chen, L.; Tao, L.; Dong, L.; Li, Y.; An, H.; Yu, X.; Wang, Q.; Chang, J. Antivir. Ther. 2012, 17, 679.
[8] Zhou, Y.; Zhang, Y.; Yang, X.; Zhao, J.; Zheng, L.; Sun, C.; Jiang, J.; Yang, Q.; Wang, Q.; Chang, J. Antivir. Ther. 2012, 17, 1593.
[9] Yang, Q.; Kang, J.; Zheng, L.; Wang, X.-J.; Wan, N.; Wu, J.; Qiao, Y.; Niu, P.; Wang, S.-Q.; Peng, Y.; Wang, Q.; Yu, W.; Chang, J. J. Med. Chem. 2015, 58, 3693.
[10] Lv, Z.; He, W.; Tian, X.; Kang, J.; Liu, Y.; Peng, Y.; Zheng, L.; Wang, Q.; Yu, W.; Chang, J. Eur. J. Med. Chem. 2015, 101, 103.
[11] Asakura, J.; Robins, M. J. J. Org. Chem. 1990, 55, 4928.
Outlines

/